• Suzhou Ribo Life Science submitted a Phase I clinical trial application in the EU for RBD3133, an INHBE-targeting siRNA obesity candidate.
• The filing seeks clearance to start a randomized, placebo-controlled first-in-human study assessing safety, tolerability, pharmacokinetics, pharmacodynamics.
• Subsidiary Ribocure Pharmaceuticals AB is included in the submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610072141PR_NEWS_USPR_____CN66713) on October 08, 2026, and is solely responsible for the information contained therein.